The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants

References

• Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924
   PubMed Web of Science ®Google Scholar
• Lai CC, Wang CY, Wang YH, et al. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55(4):105946. doi: 10.1016/j.ijantimicag.2020.105946
   PubMed Web of Science ®Google Scholar
• World Health Organization. [cited 2023 Oct 7]. Available from: https://covid19.who.int/
   Google Scholar
• Huang SM, Wu CH, Yen TY, et al. Clinical characteristics and factors associated with severe COVID-19 in hospitalized children during the SARS-CoV-2 omicron pandemic in Taiwan. J Microbiol Immunol Infect. 2023;56(5):961–969. doi: 10.1016/j.jmii.2023.06.001
   PubMedGoogle Scholar
• Lai CC, Lee PI, Hsueh PR. How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020-2022. J Microbiol Immunol Infect. 2023;56:433–441. doi: 10.1016/j.jmii.2023.04.001
   PubMedGoogle Scholar
• Song YC, Liu SJ, Lee HJ, et al. Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis. J Microbiol Immunol Infect. 2023;56(4):705–717. doi: 10.1016/j.jmii.2023.03.008
   PubMedGoogle Scholar
• Yu SY, Choi M, Cheong C, et al. Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: a living systematic review and meta-analysis. J Microbiol Immunol Infect. 2023;56(5):909–920. doi: 10.1016/j.jmii.2023.07.009
   PubMedGoogle Scholar
• Zabidi NZ, Liew HL, Farouk IA, et al. Evolution of SARS-CoV-2 variants: implications on immune escape, vaccination, therapeutic and diagnostic strategies. Viruses. 2023;15(4):15. doi: 10.3390/v15040944
   Web of Science ®Google Scholar
• Chatterjee S, Bhattacharya M, Nag S, et al. A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. Viruses. 2023;15(1):15. doi: 10.3390/v15010167
   Web of Science ®Google Scholar
• Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of omicron in South Africa. Science. 2022;376(6593):eabn4947. doi: 10.1126/science.abn4947
   PubMed Web of Science ®Google Scholar
• Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the omicron variant from previous SARS-CoV-2 infection. N Engl J Med. 2022;386(13):1288–1290. doi: 10.1056/NEJMc2200133
   PubMed Web of Science ®Google Scholar
• Torjesen I. Covid-19: omicron variant is linked to steep rise in hospital admissions of very young children. BMJ. 2022;376:o110. doi: 10.1136/bmj.o110
   PubMed Web of Science ®Google Scholar
• Hsu WH, Shiau BW, Liu TH, et al. Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis. Expert Rev Anti Infect Ther. 2023;21(10):1143–1151. doi: 10.1080/14787210.2023.2267846
   PubMed Web of Science ®Google Scholar
• Tsai YW, Wu JY, Liu TH, et al. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data. J Med Virol. 2023;95(9):e29085. doi: 10.1002/jmv.29085
   PubMedGoogle Scholar
• Wu JY, Liu MY, Liu TH, et al. The association between nirmatrelvir plus ritonavir and the outcomes of nonhospitalized obese patients with COVID-19. Int J Antimicrob Agents. 2023;62:106984. doi: 10.1016/j.ijantimicag.2023.106984
   PubMed Web of Science ®Google Scholar
• Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213–1222. doi: 10.1016/S0140-6736(22)01586-0
   PubMed Web of Science ®Google Scholar
• Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. Health system: a population-based cohort study. Ann Intern Med. 2023;176(1):77–84. doi: 10.7326/M22-2141
   PubMed Web of Science ®Google Scholar
• Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281–293. doi: 10.1016/S0140-6736(22)02597-1
   PubMed Web of Science ®Google Scholar
• Low EV, Pathmanathan MD, Chidambaram SK, et al. Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: a retrospective cohort study. Int J Infect Dis. 2023;135:77–83. doi: 10.1016/j.ijid.2023.08.003
   PubMed Web of Science ®Google Scholar
• Wee LE, Tay AT, Chiew C, et al. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during omicron BA.2, BA.4/5, and XBB transmission. Clin Microbiol Infect. 2023;29(10):1328–1333. doi: 10.1016/j.cmi.2023.06.016
   PubMed Web of Science ®Google Scholar
• Lin DY, Abi Fadel F, Huang S, et al. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections. JAMA Netw Open. 2023;6:e2335077. doi: 10.1001/jamanetworkopen.2023.35077
   PubMed Web of Science ®Google Scholar
• Palchuk MB, London JW, Perez-Rey D, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6(2):ooad035. doi: 10.1093/jamiaopen/ooad035
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. COVID data tracker: variant proportions. [cited 2023 Nov 5]. Available from: https://covid.cdc.gov/covid-data-tracker/#variant-proportions
   Google Scholar
• TriNetX publication guidelines. Available from: https://trinetx.com/real-world-resources/publications/trinetx-publication-guidelines/
   Google Scholar
• Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758–764. doi: 10.1093/aje/kwv254
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, da Silva MM G, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044
   PubMed Web of Science ®Google Scholar
• Liu TH, Wu JY, Huang PY, et al. The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: a retrospective cohort study including 91,528 patients. J Infect. 2023;86(3):256–308. doi: 10.1016/j.jinf.2023.01.014
   Web of Science ®Google Scholar
• Tsai YW, Tsai CF, Wu JY, et al. The risk of methicillin-resistant staphylococcus aureus infection following COVID-19 and influenza: a retrospective cohort study from the TriNetX network. J Infect. 2023;86(3):256–308. doi: 10.1016/j.jinf.2023.01.006
   Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi: 10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Taquet M, Luciano S, Geddes JR, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130–140. doi: 10.1016/S2215-0366(20)30462-4
   PubMed Web of Science ®Google Scholar
• Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637–1638. doi: 10.1001/jama.2015.13480
   PubMed Web of Science ®Google Scholar
• Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with covid-19. Clin Infect Dis. 2023;76(4): 563–572. doi: 10.1093/cid/ciac673
   PubMed Web of Science ®Google Scholar
• Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2022 Sep 5:ciac724. doi: 10.1093/cid/ciac724
   Google Scholar
• Møller MH, Chew MS, Olkkola KT, et al. Therapeutics and COVID-19-a living WHO guideline: endorsement by the scandinavian society of anaesthesiology and intensive care medicine. Acta Anaesthesiol Scand. 2022;66:636–637. doi: 10.1111/aas.14046
   PubMed Web of Science ®Google Scholar
• Hansen K, Makkar SR, Sahner D, et al. Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: a target trial emulation study. medRxiv. 2023 June 3. doi: 10.1101/2023.05.26.23290602
   Google Scholar
• Rabie AM. Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication. ACS Omega. 2022;7(3):2960–2969. doi: 10.1021/acsomega.1c05998
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdalla M. Forodesine and riboprine exhibit strong anti-SARS-CoV-2 repurposing potential: in silico and in vitro studies. ACS Bio Med Chem Au. 2022;2(6):565–585. doi: 10.1021/acsbiomedchemau.2c00039
   PubMedGoogle Scholar
• Eltayb WA, Abdalla M, Rabie AM. Novel investigational anti-SARS-CoV-2 agent ensitrelvir “S-217622”: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of coronavirus species. ACS Omega. 2023;8(6):5234–5246. doi: 10.1021/acsomega.2c03881
   PubMedGoogle Scholar
• Rabie AM. Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoVitris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs. New J Chem. 2021;45(2):761–771. doi: 10.1039/D0NJ03708G
   Web of Science ®Google Scholar
• Rabie AM. Teriflunomide: a possible effective drug for the comprehensive treatment of COVID-19. Curr Res Pharmacol Drug Discov. 2021;2:100055. doi: 10.1016/j.crphar.2021.100055
   PubMedGoogle Scholar
• Rabie AM, Eltayb WA. Potent dual polymerase/exonuclease inhibitory activities of antioxidant aminothiadiazoles against the COVID-19 omicron virus: a promising in silico/in vitro repositioning research study. Mol Biotechnol. 2023;2023:1–20. doi: 10.1007/s12033-022-00551-8
   Google Scholar
• Abdalla M, Rabie AMDual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant. Comput Biol Chem. 2023 Jun;104:107768. doi: 10.1016/j.compbiolchem.2022.107768
   PubMed Web of Science ®Google Scholar
• Rabie AM, MJMCR A. Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the omicron-B.1.1.529/BA. 2 subvariant: a repurposing research study. Med Chem Res. 2023;32:326–341. doi: 10.1007/s00044-022-02970-3
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdel-Dayem MA, Abdalla M. Promising experimental anti-SARS-CoV-2 agent “SLL-0197800”: the prospective universal inhibitory properties against the coming versions of the coronavirus. ACS Omega. 2023;8(39):35538–35554. doi: 10.1021/acsomega.2c08073
   PubMed Web of Science ®Google Scholar
• Rabie AM. New potential inhibitors of coronaviral main protease (CoV-Mpro): strychnine bush, pineapple, and ginger could be natural enemies of COVID-19. Int J New Chem. 2022;9:225–237. doi: 10.22034/ijnc.2022.3.10
   Google Scholar
• Rabie AM. Potent toxic effects of taroxaz-104 on the replication of SARS-CoV-2 particles. Chem-Biol Interact. 2021;343:109480. doi: 10.1016/j.cbi.2021.109480
   PubMed Web of Science ®Google Scholar
• Rabie AM. Improved synthesis of the anti-SARS-CoV-2 investigational agent (E)-N-(4-Cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (Cyanorona-20). Rev Chim. 2022;73:69–75. doi: 10.37358/RC.22.4.8555
   Google Scholar